Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech for less than cash value -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (307)	1/13/2008 5:24:56 PM
From: Gary Mohilner	Read Replies (1) \| Respond to of 684

As I understand this trial it's for patients who don't have Mets, but for whom the SOC is 11 months, not 5 years. I don't know if the drug will have much benefits for patients with Mets, but even if not, it may extend or save the life of many who don't. If in fact the drug does give 19 months on average to patients that the SOC only gives 11, I believe it should be approved for that application on the next peek at the data. Cures are a rarity with Pancreatic Cancer, but if the cancer's being killed by the drug I don't know that it can't work its way through the Mets, but that would be the subject of a completely different trial. For now approval would only be for patients without Mets. Of course everyone knows it will be tried off label for other applications, it's actually getting some good results in Phase II in other cancers, so expansion of the applications should almost certainly come, whether it includes Pancreatic cancer with mets or not. Gary

To: scaram(o)uche who wrote (307)	1/23/2008 10:58:30 PM
From: Jibacoa	Read Replies (1) \| Respond to of 684

O.T. I am still waiting for the results of the PI of IT-101, which are supposed to be ready any time.<g> clinicaltrials.gov According to the story by By Jerry Adler in the Nov 12, 2007 Issue of NEWSWEEK, at the time of the first trials, there was also a questionable pancreatic Ca. "cure". newsweek.com IT-101, went into the first phase of clinical trials, intended to establish a safe dosage. The problem was that it worked almost too well. His very first patient, a young man with pancreatic cancer who was given only about three months to live, is still alive today, more than a year later. Good results were also seen in patients with "massive" lung and kidney tumors. Of course, ARWR has also some interesting subsidiaries.<g> Message 24029818 Bernard